San Diego, CA – According to filings with the U.S. Securities and Exchange Commission, ViaCyte is raising $36,018,634.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Paul Laikind played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About ViaCyte

ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments that will reduce or eliminate the need for blood glucose monitoring, insulin administration, and the risks of hypoglycemia and diabetes-related complications. ViaCyte has two products in clinical development. The first is called the PEC-Direct product candidate, which delivers proprietary pancreatic progenitor cells (PEC-01 cells) in a non-immunoprotective device.

To learn more about ViaCyte, visit http://www.viacyte.com/

Contact:
Paul Laikind, Chief Executive Officer
858-207-0500
plaikind@viacyte.com
https://www.linkedin.com/in/plaikind/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved